Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Non-Current Deffered Revenue (2020 - 2023)

Candel Therapeutics' Non-Current Deffered Revenue history spans 4 years, with the latest figure at $108000.0 for Q3 2023.

  • For Q3 2023, Non-Current Deffered Revenue changed N/A year-over-year to $108000.0; the TTM value through Sep 2023 reached $108000.0, changed N/A, while the annual FY2022 figure was $144000.0, 83.89% down from the prior year.
  • Non-Current Deffered Revenue for Q3 2023 was $108000.0 at Candel Therapeutics, down from $120000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $894000.0 in Q4 2021 and bottomed at $31000.0 in Q3 2021.
  • The 4-year median for Non-Current Deffered Revenue is $138000.0 (2022), against an average of $330250.0.
  • The largest annual shift saw Non-Current Deffered Revenue skyrocketed 41.46% in 2021 before it crashed 83.89% in 2022.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $632000.0 in 2020, then surged by 41.46% to $894000.0 in 2021, then plummeted by 83.89% to $144000.0 in 2022, then fell by 25.0% to $108000.0 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Non-Current Deffered Revenue are $108000.0 (Q3 2023), $120000.0 (Q2 2023), and $132000.0 (Q1 2023).